Cyclic vomiting syndrome (CVS): symptoms, diagnosis, treatment and supplement evidence

What is cyclic vomiting syndrome? Cyclic vomiting syndrome (CVS), also called cyclical vomiting syndrome, causes repeated attacks of severe nausea and vomiting separated by better periods. It affects children and adults; diagnosis depends on the pattern and appropriate assessment for other causes. NIDDK: episode pattern.

Confidence: recognition, dehydration care and a clinician-written episode plan are established care priorities. Evidence for specific preventive medicines and supplements is less certain and often indirect. This review does not establish a financially independent best supplement or drug. A familiar CVS diagnosis does not make blood, green vomit, severe pain or neurological changes safe to observe at home.

Table of contents

• Evidence summary
• CVS attacks, better periods and related diagnoses
• Migraine, gut–brain signalling and triggers
• Assessment and the separate rescue and prevention plans
• CoQ10, riboflavin and nutrition: what the evidence can show
• Reading improvement, treatment claims and product promotion
• Dehydration and emergency signs during a vomiting attack
• Medicine and supplement interactions to disclose
• Children, pregnancy and cannabis-associated vomiting
• A written episode plan and useful follow-up questions
• Mitochondrial theories and the human-evidence boundary
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

CVS attacks, better periods and related diagnoses

An attack can disrupt eating, sleeping, school and work. The recognizable pattern is repeated severe nausea and vomiting, often resembling previous attacks. Better intervals help distinguish that history from an isolated infection or continuously worsening symptoms, although the diagnosis cannot be made from timing alone. NIDDK: clinical definition.

Adults may retain milder nausea or digestive discomfort between major attacks. “You must feel completely normal every day between episodes” is therefore too rigid. A change toward more continuous symptoms still deserves reassessment: the original pattern, new medicines and alternative explanations matter. Dated adult guideline: interval symptoms.

The description cyclical does not imply a perfectly scheduled calendar. Keep the dates and circumstances rather than assuming that every episode must arrive at an identical interval. The history should show what actually happens, including an apparently well period that is shorter or less well than it used to be. NHS: symptom history.

Migraine, gut–brain signalling and triggers

The cause is not fully understood. Migraine in the person or family can be relevant, and autonomic symptoms such as pallor and sweating can accompany attacks. These associations help clinicians understand the illness; they do not prove that one nutrient deficiency or one psychological event explains every case. NHS: causes and accompanying symptoms.

Stress, excitement, interrupted sleep, illness or going too long without food can appear in an episode history. Recording an association does not establish causation. A diary is more useful when it includes ordinary symptom-free days, since an event that happens frequently may coincide with an attack by chance. This is a practical way to discuss the trigger information, rather than a demand that the patient control every aspect of life. NIDDK: trigger discussion.

Assessment and the separate rescue and prevention plans

A clinician asks about the onset, duration, recovery, family history, medicines and substance use, and examines for clues to another cause. Blood, urine, imaging or endoscopy can answer particular questions. A normal single test does not independently confirm CVS, and the word functional should not be used to close the investigation before appropriate assessment. NIDDK: assessment purposes.

The August 2025 child-diagnosis guideline supports limited serum/urine testing and an upper-GI contrast series, with additional evaluation guided by alarms or atypical progression. Its diagnostic-strategy evidence is very low certainty. It is pediatric guidance, not an adult test order or a reason to ignore deterioration while awaiting a routine appointment. Original 2025 child-diagnosis guideline.

Care distinguishes an early warning phase, active vomiting, recovery and the period between attacks. A rescue plan tries to control an episode; a preventive plan aims to reduce future disruption. Which medicines, routes and monitoring fit depends on age and medical history. The older government phase explanation remains useful, but its historical drug list is not a current shopping list. NIDDK: phase-based context.

Adult clinical guidance discusses options such as amitriptyline for prevention and anti-sickness or migraine-directed rescue treatment. This is clinical context rather than an independently verified ranking. A medicine used for another diagnosis may have a different purpose here; its name does not determine the diagnosis or remove the need to explain risks. 2019 adult treatment context.

CoQ10, riboflavin and nutrition: what the evidence can show

CoQ10 is often discussed as part of a mitochondrial supplement approach. An original 2010 CVS study used an internet survey of patients or parents, with self-selected treatment histories. It was not a blinded randomized comparison. Recall, unequal groups, different formulations and uncertain diagnosis verification limit the conclusions. Similar reported improvement cannot demonstrate that two treatments are equivalent. Original survey and limitations.

The 2025 child-management guideline relies substantially on migraine evidence for several supplement suggestions. It does not establish strong direct CVS evidence for magnesium or riboflavin, and concludes that evidence is insufficient for L-carnitine alone. An indirect recommendation and an independent condition-specific treatment effect are different claims. Original supplement evidence review.

Adequate nutrition between episodes and return to eating during recovery are separate from supplement efficacy. NIDDK’s dated nutrition page discusses avoiding prolonged missed meals and recovering intake. A dietitian can help when fear of another episode narrows the diet. Blanket exclusions, routine fasting or replacing meals with a supplement can create another problem without establishing control of CVS. NIDDK: interval nutrition.

Reading improvement, treatment claims and product promotion

An episode plan should be judged against meaningful outcomes: ability to retain intake, episode disruption, urgent-care visits and adverse effects. Those observations are useful for the next clinical discussion. They cannot by themselves isolate which component caused a change when several medicines, routines or supplements changed together. This is an evidence limitation, not a reason to discount someone’s improvement. Original observational-design limitations.

The CVSA supplement page contains seller discounts and product/bioavailability promotion. Its original text does not disclose all contractual or commission arrangements. A price concession is not a therapeutic outcome. This guide excludes those promotional efficacy claims from its independent verdict and does not select a supplement brand from them. CVSA: commercial relationship disclosure.

For a child, the 2025 treatment document contains age-specific decisions and many conditional recommendations. The practical implication is to ask which recommendation applies and what uncertainty remains, rather than treating a society logo as proof that every option has equally strong evidence. Original pediatric treatment scope.

Dehydration and emergency signs during a vomiting attack

Get urgent help when repeated vomiting prevents fluids staying down, urine becomes noticeably less frequent or a baby has fewer wet nappies. In the UK, contact NHS 111; call rather than use online assessment for a child under five. A pre-existing episode plan should identify when rescue care has failed and where to seek help. NHS: urgent dehydration advice.

Blood or coffee-ground vomit, green vomit in an adult, or yellow-green/green vomit in a child requires emergency assessment. So do sudden severe abdominal pain or headache, a stiff neck with light sensitivity, confusion, severe breathing difficulty or abnormal pale/blotchy skin. Use 999/A&E in the UK or the local emergency service elsewhere; do not drive yourself. NHS: vomiting emergency warnings.

Forceful vomiting can injure the lining near the stomach junction and cause a Mallory–Weiss tear. That possibility does not make bleeding routine or prove the cause at home. A complication and the underlying vomiting syndrome may both need care. Tell clinicians what changed rather than assuming the new symptom belongs to the usual attack. Cleveland Clinic: lining injury.

Medicine and supplement interactions to disclose

Take the full medicine list to the consultation, including prescriptions from other specialists and all over-the-counter products. Treatment may need a usable route when oral intake is difficult. Do not substitute a borrowed anti-sickness drug or repeat doses on your own because vomiting makes absorption uncertain. Your team should specify what to do when the intended rescue medicine cannot be retained. NIDDK: hospital versus outpatient treatment.

CoQ10 can interact with warfarin and insulin and may be unsuitable with some cancer treatments. Its adverse effects can include digestive upset or insomnia. “Natural” and “mitochondrial” do not clear those interactions. The NCCIH source is dated January 2019; it provides safety context, not a CVS efficacy verdict. NCCIH: CoQ10 safety.

Give the clinician the product label and explain the actual amount used, rather than saying only “vitamins”. Concentrated combinations can contain more than one active ingredient. A supplement discussion should include cost, monitoring and a stopping/review decision, not only the hoped-for mechanism. NCCIH: disclosure and supplement decisions.

Children, pregnancy and cannabis-associated vomiting

The 2025 diagnosis document supersedes the 2008 pediatric consensus. Severe vomiting needs assessment before any historical episode count has accumulated. Original updated child assessment.

Disclose cannabis use: it does not automatically prove cannabinoid hyperemesis syndrome (CHS). The guideline considers CHS separately, using the exposure, alternatives and cessation history. A CVS label is not proof that cannabis treats vomiting. CHS diagnostic context.

Pregnancy-associated vomiting requires its own assessment, particularly when intake is poor or dehydration develops. Someone with established CVS can still have hyperemesis gravidarum or another problem. Tell the team about pregnancy and existing medicines so that the cause, medicine suitability and hydration needs can be considered together. NHS: pregnancy vomiting.

A written episode plan and useful follow-up questions

Ask the treating team for a written plan covering early signs, prescribed rescue treatment, failure to retain fluids or medicine, and the appropriate urgent-care route. A summary that can be shown to emergency staff helps communicate the established history while allowing them to reassess new findings. It should not ask staff to assume that every future vomiting event is CVS. Adult guidance: individualized emergency protocol.

A diary can record dates, duration, recovery, possible triggers and what was taken. Include missed school/work and whether emergency fluids were needed. Bring it to review with the prescription list. These records turn an unclear account of “better” or “worse” into concrete information without asking the patient to diagnose the mechanism. NHS: diary and clinical management.

During a familiar episode without emergency signs, small tolerated sips and pharmacist-guided oral rehydration can help. Persistent inability to retain fluid needs urgent advice rather than repeated home experiments. Older people, babies and people with other medical conditions may need earlier assessment. NHS: hydration and vulnerable groups.

Mitochondrial theories and the human-evidence boundary

A proposed energy-metabolism mechanism does not mean that all CVS is a proven inherited mitochondrial disease. A laboratory finding cannot establish that a commercial mixture prevents human episodes. This guide keeps mechanistic hypotheses separate from diagnosis, human treatment outcomes and financially independent verification. Animal or in-vitro results are not counted as clinical efficacy. NIDDK: disease context.

The independent conclusion is limited: carefully assessed CVS warrants an episode plan and appropriate acute support; supplement superiority and a universal preventive regimen are not established here. New symptoms, changed patterns or poor response should reopen the clinical discussion, rather than automatically trigger a more elaborate supplement stack. NIDDK: reconsidering causes.

Funding and source roles

Public institutions, professional societies and a patient association serve different roles. The NIDDK pages are dated education with an outside reviewer; the guidelines name CVSA funding and separate commercial interests. Public hosting does not clear the original studies. Financially interested efficacy claims are excluded from the independent verdict; incomplete chains remain explicitly unclassified.

Frequently asked questions

Can adults have cyclic vomiting syndrome?

Yes. Childhood onset is not required, and adults may have milder symptoms between major episodes. A clinician should evaluate the actual history rather than use a child’s diagnostic checklist.

Does a normal scan prove CVS?

No. Tests help assess alternatives; the episode pattern and examination remain relevant. Alarm signs or a changed pattern can require additional evaluation.

Is CoQ10 a proven replacement for prescribed prevention?

No. The reviewed CVS survey cannot prove equivalence, and newer supplement recommendations often depend on indirect evidence. Discuss any trial of treatment and its monitoring with the team.

When should a familiar attack be treated as an emergency?

Blood/coffee-ground or green vomit, severe sudden pain, neurological changes, severe breathing difficulty or collapse require emergency assessment. Inability to keep fluid down and reduced urine need urgent advice.

Sources and funding notes

Originals checked 4 October 2026. NIDDK CVS pages are December 2017; numerical historical diagnosis rules and drug lists are not adopted. NHS CVS is May 2024, due 2027; general vomiting December 2023, due December 2026. Child management was first online April 2025 with a May heading correction; child diagnosis August 2025. The adult university manuscript is dated 2019; its separate disclosure supplement was not retrieved and recommendation-strength wording is not adopted. NCCIH CoQ10 is January 2019, not its 2026 footer. Financial routes do not independently establish clinical benefit.

1. NIDDK: December 2017 CVS definition — Episode pattern and complications; dated population/race estimates not adopted.
2. NIDDK: December 2017 CVS diagnostic context — History, examination and selective test purposes; its 2008 child criteria and numeric adult criteria are not presented as current diagnostic rules.
3. NIDDK: December 2017 phase-based CVS care — Prodrome, vomiting, recovery and interval care; historical ranitidine and other drug lists, doses and IV recipes not adopted.
4. NIDDK: December 2017 CVS nutrition context — Recovery and adequate interval nutrition; blanket food exclusions, branded drinks and older supplement lists not adopted.
5. NHS: May 2024 cyclical-vomiting original — Episode description, diary and clinical review; monthly episode threshold not used to delay assessment or decide treatment.
6. ANMS/CVSA: 2019 adult guideline author manuscript — Adult interval symptoms, clinical options and individualized emergency plan. Recommendation-strength wording, old Rome numerical criteria, regimens and response percentages not adopted.
7. NASPGHAN: April 2025 child-management guideline — Age-specific treatment and supplement uncertainty; April 14 publication/May 9 heading correction. No dose, device preference, migraine-to-CVS causal benefit or independent drug ranking.
8. NASPGHAN: August 2025 child-diagnosis guideline — First online 20 August 2025: limited baseline testing plus alarm-directed evaluation; child guideline, not an adult self-diagnostic rule.
9. Boles and colleagues: original 2010 CoQ10 survey — Survey design and limitations only; percentages, equivalence, product superiority and personalized dosing excluded from independent verdict.
10. Ohio State: original 2022 reviewer disclosure metadata — Financial provenance only; no efficacy claims or inference that the 2017 page itself was company-funded.
11. CVSA: own fundraising and office original — Funder is Cyclic Vomiting Syndrome Association, not the unrelated Commercial Vehicle Safety Alliance.
12. CVSA: own supplement-discount page — Commercial relationships only; product endorsements, high-dose lists and superiority claims excluded.
13. ANMS Institute: own corporate-partner original — Society support routes, separate from CVSA’s stated adult-guideline project funding.
14. NASPGHAN Foundation: original 2025 biennial report — Commercial support route; no assertion a named company funded either CVS guideline directly.
15. NASPGHAN: own national-office contact — Jurisdiction only; NASPGHAN and Foundation are related but distinct entities.
16. NCCIH: January 2019 CoQ10 safety original — Warfarin/insulin/cancer-treatment interactions and mild adverse effects; not independent CVS efficacy.
17. NHS: December 2023 general vomiting original — Red flags, small tolerated sips and high-risk groups; no home prescription or automatic stomach-bug diagnosis.
18. NHS: dehydration — Actually 1 May 2026: reduced urine, urgent dehydration and emergency deterioration; no universal fluid volume.
19. NHS: vomiting during pregnancy — Actually 17 April 2024: new pregnancy-associated vomiting and hyperemesis require their own assessment, not automatic attribution to established CVS.
20. Cleveland Clinic: July 2026 Mallory–Weiss original — Actually 16 July 2026: forceful-vomiting mucosal bleeding complication; bleeding remains an emergency warning in the CVS/general-vomiting sources.
21. Cleveland Clinic: original audited 2025/2024 accounts — Printed pp9–12, 18–20, 22 and 32 identify routes; no claim of complete June 2026 interim or page-specific independence.
22. Cleveland Clinic: advertising policy — Ad-finance route and stated editorial safeguards, not disease efficacy.
23. Cleveland Clinic: editorial policy — Process context; not a guarantee that every clinical sentence is accurate or financially independent.
24. NCCIH: supplements and medicine safety — Medicine/supplement disclosure and interaction risks; no independent CVS cure established.
25. NHS England: national 2024–2025 accounts — National patient-information provenance only.
26. NIDDK: original institutional budget — Institutional financing only; the GI series explicitly thanks an outside expert with separately disclosed commercial ties.
27. NCCIH: federal budget — Public institutional education funding, separate from product and trial finance.

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.